The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint

Abstract Type 2 diabetes mellitus (T2DM) and essential hypertension are often associated, and retrospective data analyses suggest an association between lower blood pressure (BP) values and lower cardiovascular (CV) risk in patients with T2DM. However, the most recent intervention trials fail to dem...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2014-06, Vol.24 (6), p.577-584
Hauptverfasser:	Frontoni, S, Solini, A, Fioretto, P, Natali, A, Zuccalà, A, Cosentino, F, Penno, G
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Factors Aged Aged, 80 and over Anti-hypertensive treatment Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Biomarkers Blood Pressure - drug effects Blood pressure target Cardiovascular Cardiovascular Diseases - complications Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Diabetes Mellitus, Type 2 - complications Diabetic Angiopathies - complications Diabetic Angiopathies - drug therapy Diabetic Cardiomyopathies - complications Diabetic Cardiomyopathies - epidemiology Diabetic Cardiomyopathies - prevention & control Drug Monitoring Elderly Evidence-Based Medicine Humans Hypertension - complications Hypertension - drug therapy International Agencies J-shaped curve Medicin och hälsovetenskap Middle Aged Practice Guidelines as Topic Precision Medicine Risk Factors Societies, Medical Societies, Scientific Type 2 diabetes Voluntary Health Agencies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Type 2 diabetes mellitus (T2DM) and essential hypertension are often associated, and retrospective data analyses suggest an association between lower blood pressure (BP) values and lower cardiovascular (CV) risk in patients with T2DM. However, the most recent intervention trials fail to demonstrate a further CV risk reduction, for BP levels
ISSN:	0939-4753 1590-3729 1590-3729
DOI:	10.1016/j.numecd.2014.01.004